• I-Tech's Q3 2026 net profit rose 24% to SEK 11.62 million; net sales climbed 19% to SEK 48.76 million.
• Operating cash flow fell 43% to SEK 13.29 million, while cash and cash equivalents reached SEK 177.22 million at September-end.
• EU member states are voting October 7–21 on medetomidine’s proposed non-renewal; preparations to legally challenge any negative decision are complete.
• September brought an exclusive worldwide license agreement with Titanium Technology to develop and commercialize non-biocidal electrochemical antifouling technology for aquaculture.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. I-Tech AB published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein.